Becker Capital Management Inc. Sells 45,719 Shares of Sanofi $SNY

Becker Capital Management Inc. decreased its holdings in Sanofi (NASDAQ:SNY) by 8.0% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 522,681 shares of the company’s stock after selling 45,719 shares during the period. Becker Capital Management Inc.’s holdings in Sanofi were worth $24,671,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Raymond James Financial Inc. increased its holdings in shares of Sanofi by 81.3% in the 2nd quarter. Raymond James Financial Inc. now owns 5,879,894 shares of the company’s stock valued at $284,058,000 after acquiring an additional 2,635,867 shares during the period. Franklin Resources Inc. boosted its position in Sanofi by 9.9% during the second quarter. Franklin Resources Inc. now owns 4,274,410 shares of the company’s stock valued at $206,497,000 after purchasing an additional 384,902 shares in the last quarter. Mondrian Investment Partners LTD purchased a new position in Sanofi in the third quarter valued at about $171,742,000. Equity Investment Corp raised its holdings in Sanofi by 3.0% in the third quarter. Equity Investment Corp now owns 2,587,690 shares of the company’s stock worth $122,139,000 after purchasing an additional 75,255 shares in the last quarter. Finally, Brandes Investment Partners LP lifted its position in shares of Sanofi by 9.1% during the second quarter. Brandes Investment Partners LP now owns 2,483,767 shares of the company’s stock valued at $119,992,000 after buying an additional 208,090 shares during the last quarter. Institutional investors own 14.03% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. Guggenheim downgraded shares of Sanofi from a “buy” rating to a “neutral” rating in a research report on Tuesday, December 9th. Wall Street Zen downgraded shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 21st. Bank of America downgraded Sanofi from a “buy” rating to a “neutral” rating in a research report on Thursday, February 12th. UBS Group reissued a “neutral” rating on shares of Sanofi in a research report on Friday, January 16th. Finally, HSBC restated a “buy” rating on shares of Sanofi in a research note on Wednesday, December 10th. Five analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $62.67.

Sanofi Price Performance

Shares of SNY opened at $48.66 on Monday. The business’s 50-day moving average is $47.54 and its two-hundred day moving average is $48.58. The company has a market capitalization of $118.68 billion, a P/E ratio of 13.52, a P/E/G ratio of 1.26 and a beta of 0.45. Sanofi has a fifty-two week low of $44.62 and a fifty-two week high of $60.12. The company has a debt-to-equity ratio of 0.20, a quick ratio of 0.73 and a current ratio of 1.09.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.